A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Latest Information Update: 29 Apr 2024
At a glance
- Drugs Rupitasertib (Primary) ; Elacestrant; Tamoxifen; Trastuzumab
- Indications HER2 negative breast cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors EMD Serono
- 22 Apr 2024 Data from this study were published in the Journal of Hematology & Oncology.
- 19 Apr 2023 Results (n=20) assessing the exploratory correlative analyses in ER+ HER2-negative metastatic breast cancer patients in addition to nonclinical experiments to evaluate its role in the CDK4/6 and endocrine therapy (ET) resistant setting, presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 06 Apr 2023 According to Diaccurate Media Release, DIACC3010, expectedto enter phase 2/3 clinical trial in refractory ER positive and HER negative Metastatic breast cancer and phase 1 trial in glioblastoma multiforme.